Not only can RT achieve therapeutic effects in terms of systemic immune cells through Treg, but it was also found that in a poorly immunogenic mouse cancer model, RT treatment after the blockade of TGFβ effectively generated CD8+ T cell responses against multiple endogenous tumor antigens and inhibited tumor growth [277]. The gene discussed is TGFB1; the disease is neoplasm.